Mass spectrometry platform could shrink cancer drug discovery cycle to four hours
Purdue researchers have unveiled a game-changing mass spectrometry platform that could shrink the notoriously slow cancer drug discovery cycle to a mere four hours, a dramatic acceleration from the typical days or weeks. Developed by the Purdue Institute for Cancer Research (PICR), this ultrahigh-throughput system integrates chemical synthesis, biological testing, and advanced mass spectrometry into a seamless, automated workflow, directly targeting one of the biggest bottlenecks in bringing new cancer therapies to patients.













